BIIB

Biogen Inc.

Price

$178.96

return (12m)

p/e

22.13

p/bv

1.63

DIVIDEND YIELD

0.00%

BIIB price

Biogen

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment BIIB

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals BIIB

Valuation

P/E

22.13

Sector -4.15

Industry -4.15

P/BV

1.63

Sector 2.06

Industry 2.06

P/Revenue (PSR)

3.05

Sector -4.16

Industry -4.16

EV/EBITDA

49.81

Sector -241.86

Industry -241.86

EV/EBIT

72.67

Sector -671.75

Industry -671.75

P/EBITDA

11.25

Sector -4.30

Industry -4.30

P/EBIT

15.99

Sector -4.35

Industry -4.35

P/Total Assets

1.03

Sector 1.46

Industry 1.46

P/Net Current Assets

-18.50

Sector -12.67

Industry -12.67

P/Working Capital

4.90

Sector -12.58

Industry -12.58

EPS

9.33

Sector -2.19

Industry -2.19

BVPS

126.88

Sector 1.92

Industry 1.92

Efficiency

Gross Margin

75.49%

Sector 36.44%

Industry 36.44%

EBITDA Margin

26.22%

Sector -16,748.51%

Industry -16,748.51%

EBIT Margin

17.97%

Sector -4,256,846.44%

Industry -4,256,846.44%

Operating Margin

23.18%

Sector -38.78%

Industry -38.78%

Net Profit Margins

13.81%

Sector -39.93%

Industry -39.93%

Asset Turnover

0.08

Sector 0.03

Industry 0.03

Profitability

ROE

7.36%

Sector -67.01%

Industry -67.01%

ROA

4.65%

Sector -66.28%

Industry -66.28%

ROIC

6.91%

Sector -2,917.75%

Industry -2,917.75%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

3.06

Sector 2.90

Industry 2.90

Net Debt / EBITDA

3.09

Sector -12,252,405.04

Industry -12,252,405.04

Net Debt / EBIT

4.50

Sector -3.79

Industry -3.79

Net Debt / Equity

0.11

Sector -33,290.93

Industry -33,290.93

Gross Debt / Equity

0.34

Sector 0.00

Industry 0.00

Equity/Assets

0.63

Sector 0.42

Industry 0.42

Liabilities/Assets

0.37

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

-1.98%

Sector -

Industry -

5Y Earnings CAGR

-2.49%

Sector -

Industry -

FAIR VALUE OF Biogen ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$178.96

Fair Value

$163.20

Upside Return potential.

-8.80%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals BIIB

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
BIIB Biogen Inc.	$178.96	55.39%	0.00%	22.13	1.63	7.36%	13.81%
AZN AstraZeneca PLC	$204.64	53.45%	1.89%	25.20	5.52	21.93%	17.19%
JNJ Johnson & Johnson	$240.16	62.69%	2.08%	28.83	0.00	-%	21.48%
NBIX Neurocrine Biosciences Inc.	$130.81	43.95%	0.00%	25.46	5.00	19.62%	21.55%
ABEO Abeona Therapeutics Inc.	$5.19	12.83%	0.00%	6.09	2.78	45.63%	100.00%
PFE Pfizer Inc.	$27.11	32.71%	6.97%	18.76	1.55	8.29%	11.83%
ABBV AbbVie Inc.	$210.26	25.08%	2.61%	125.53	-69.01	-54.98%	5.79%
ABUS Arbutus Biopharma Corporation	$4.35	38.54%	0.00%	5.66	3.50	61.77%	83.94%
ACAD ACADIA Pharmaceuticals Inc.	$22.02	51.03%	0.00%	11.55	3.48	30.10%	34.30%
ADMA ADMA Biologics Inc.	$10.49	-45.93%	0.00%	12.58	5.33	42.37%	32.43%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

BIIB Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Biogen

Biogen Inc.

Average Investor10 user rating

4.0 (0 people)

States of America

48 years

Founded: 1978

1991

Time since IPO - 35 years

9.100

Employees

Biogen Inc. (States of America) is listed on the Nasdaq and has a market capitalization of $30.36 billion, with shareholders equity totaling $18.65 billion.

The company employs approximately 9.100 people and operates in the Healthcare sector, within the Biotecnologia industry.

Over the past 12 months, Biogen Inc. reported $9.94 billion in revenue, generating net income of $1.37 billion.

Key financial metrics include a P/E ratio of 22.13, a price-to-book (P/B) ratio of 1.63, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker BIIB.

Market cap

$30.36 billion

Net worth

$18.65 billion

$18,651,700,000.00

Assets

$29.48 billion

$29,483,100,000.00

Total Shares Outstanding

147.00 million

147,000,000

Average Daily Trading Volume

$1.30 million

$1,304,708.00

Sector

Healthcare

Industry

Biotecnologia

BIIB

revenue by Business Segment Biogen

BIIB revenue and profits

Financial Results BIIB

DRAG THE FRAME TO SEE MORE DATA

BIIB cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$862.96 22,54% (12M)

P/E

21.66

0.39%

ROE

-570.98%

P/BV

-123.68

CAH - Cardinal Health

$214.95 38,63% (12M)

P/E

34.90

0.89%

ROE

-58.20%

P/BV

-20.31

JNJ - Johnson & Johnson

$240.16 47,25% (12M)

P/E

28.83

2.08%

ROE

P/BV

0.00

MRK - Merck & Co.

$119.96 46,43% (12M)

P/E

35.53

2.62%

ROE

19.45%

P/BV

6.91

AZN - AstraZeneca

$204.64 40,78% (12M)

P/E

25.20

1.89%

ROE

21.93%

P/BV

5.52

ABBV - AbbVie

$210.26 15,08% (12M)

P/E

125.53

2.61%

ROE

-54.98%

P/BV

-69.01

NVO - Novo Nordisk

$39.32 --40,26% (12M)

P/E

11.83

3.68%

ROE

60.40%

P/BV

7.14